Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma
Authors:
Open Access
- 9 September 2024
- Vol. 79 (11) , 2993-3004
Abstract
Background: Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an anti‐tryptase antibody, in a phase 2a randomized trial for patients with uncontrolled asthma and a phase 1c trial to understand activity within the lower respiratory tract.Methods: Phase 2a patients (n = 134) received 1800 mg MTPS9579A or placebo intravenously every 4 weeks for 48 weeks. The primary endpoint was time to the first composite exacerbation event. Phase 1c patients (n = 27) received one intravenous dose of 300 or 1800 mg MTPS9579A or placebo. Both trials measured MTPS9579A concentrations and effects on tryptase in serum and nasal lining fluid; phase 1c also analyzed bronchial lining fluid.Results: MTPS9579A did not meet the primary endpoint (hazard ratio = 0.90; 95% CI: 0.55–1.47; p = 0.6835); exacerbation rates in the placebo group were low. Serum and nasal MTPS9579A pharmacokinetics and tryptase levels were consistent with data from healthy volunteers. However, in phase 1c patients, compared to nasal levels, MTPS9579A bronchial concentrations were 6.8‐fold lower, and bronchial active and total tryptase levels were higher (119‐fold and 30‐fold, respectively). Pharmacokinetic/pharmacodynamic modeling predicted intravenous doses of 3800 mg every 4 weeks would be necessary to achieve 95% active tryptase inhibition from baseline.Conclusions: The MTPS9579A dose tested in the phase 2a study was insufficient to inhibit tryptase in bronchial lining fluid, likely contributing to the observed lack of efficacy.Keywords
Funding Information
- Genentech
- National Institute for Health and Care Research
This publication has 36 references indexed in Scilit:
- Asthma exacerbations during the pandemic: Time to rethink clinical markersJournal of Allergy and Clinical Immunology: Global, 2022
- Mast cell tryptases in allergic inflammation and immediate hypersensitivityCurrent Opinion in Immunology, 2021
- National decline in asthma exacerbations in United States during coronavirus disease 2019 pandemicAnnals of Allergy, Asthma & Immunology, 2021
- An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe AsthmaCell, 2019
- Regional Differences in Airway Epithelial Cells Reveal Tradeoff between Defense against Oxidative Stress and Defense against RhinovirusCell Reports, 2018
- Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanismsJournal of Allergy and Clinical Immunology, 2015
- Distinct TLR-mediated pathways regulate house dust mite–induced allergic disease in the upper and lower airwaysJournal of Allergy and Clinical Immunology, 2013
- Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polypsJournal of Allergy and Clinical Immunology, 2012
- Tryptase genetics and anaphylaxisJournal of Allergy and Clinical Immunology, 2006
- Patterns of Anaphylaxis: Acute and Late Phase Features of Allergic Reactions2004